Therapeutic effects of gp96 vaccines against established myeloma. Balb/c mice (5 per group) were inoculated subcutaneously with tumor-A cells, and when subcutaneous tumors reached 25 mm2, received 3 subcutaneous injections at 3-day intervals of (A) normal gp96N, autologous gp96A, or pooled heterologous gp96BC or gp96BCD; or (B) gp96N, CpG; gp96BCD, gp96BCD + GM-CSF, IL-12; or Balb/c mice (5 per group) were inoculated subcutaneously with tumor-A cells, and when subcutaneous tumors reached 100 mm2, received 3 subcutaneous injections at 3-day intervals of (C) gp96N, CpG; gp96BCD, gp96BCD + GM-CSF, IL-12; or (D) gp96N, rat control IgG (IgG-ctrl), gp96BCD or gp96BCD + CpG combined with anti-CD25, B7H1, or IL-10 mAbs. Tumor burdens were measured twice every week. Mice were killed when subcutaneous tumors reached 225 mm2 or when mice became moribund. Results shown are measurements of tumor burdens and survival of mice that received different treatments. Representative results of 1 of 2 independent experiments are shown. *P < .05; **P < .01 (compared with controls).
